OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Rhea-AI Summary
OnKure Therapeutics (Nasdaq: OKUR) announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York from September 14–16, 2026. The management team plans to host one-on-one meetings with investors, who are advised to contact their Morgan Stanley representative to arrange meeting times.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 04 | Q2 earnings report | Positive | +1.5% | Reported quarterly results, program progress, and cash runway extending into 2029. |
| Jul 02 | KOL event notice | Neutral | +2.7% | Announced a virtual expert event focused on PI3Kα inhibitor selectivity and design. |
| May 05 | Earnings and financing | Negative | -10.0% | Reported quarterly results alongside a $150 million private placement and program updates. |
| Mar 27 | Private placement | Negative | -13.1% | Announced an oversubscribed $150 million financing for two inhibitor candidates. |
| Mar 12 | Full-year earnings | Positive | +7.4% | Reported financial results, enrollment milestones, and planned next-generation candidate updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with the March financing announcement and May earnings update followed by negative moves, while other recent announcements were positive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.
The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to schedule meetings.
About OnKure Therapeutics
OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.
For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.
Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
